A 52‐week open‐label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine
The OLE data showed favorable tolerability and sustained and increasing treatment benefits with rimegepant 75 mg (EOD and as-needed dosing) over 52 weeks for the preventive treatment of migraine. NCT03732638.
Authors
- David Kudrow
- Robert Croop (ORCID: https://orcid.org/0009-0004-0151-1192)
- Alexandra Thiry
- Richard Lipton
Institutions
- Albert Einstein College of Medicine (US)
- Pfizer (United States) (US)
- Biohaven Pharmaceuticals (United States) (US)
- California Medical Clinic for Headache (US)
Publication Details
- Journal
- Headache The Journal of Head and Face Pain
- Published
- 2025-06-30
- DOI
- https://doi.org/10.1111/head.15002
- Citations
- 7
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 10.30
Funders
- Pfizer